Tradestie Institutional Equity Comparison Engine

MCRB vs CGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical while MCRB counters with relative strength in Options & Structure. Fundamentally, MCRB trades at 10.8x Forward P/E with -3115.1% operating margin (+68.9% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, MCRB sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
MCRB 10.8x vs CGEN 12.4x Fwd P/E
Growth & Margin Winner CGEN
Op Margin -3115.1% vs 41.3% ยท YoY +68.9% vs +102.1%
Momentum & Technical Winner CGEN
1Y -91.5% vs +23.2% ยท 52W Pos 0% vs 33%
Options & Structure Winner MCRB
BREAKDOWN (22nd %ile IV) vs BREAKDOWN (57th %ile IV)
MCRB NASDAQ
Seres Therapeutics, Inc.
Pharmaceutical Preparations
$1.41
+0.0% 1D
Market Cap $13.8M
1M Return -41.74%
1Y Return -91.54%
Forward P/E 10.8x
Unified AI Score
50.0 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 66.0 Mom 63.9
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MCRB -91.54% CGEN +23.17% Spread: +114.71 pp (CGEN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MCRB Revenue CGEN Revenue MCRB Op. Margin CGEN Op. Margin Margin Edge
FY2018 $30M $20M -372.6% -130.5% CGEN
FY2019 $30M N/A -264.4% N/A MCRB
FY2020 $10M $0M -740.8% -1574.8% MCRB
FY2021 $140M $10M -44.8% -584.6% MCRB
FY2022 $10M $10M -2524.0% -471.7% CGEN
FY2023 N/A $30M N/A -38.8% CGEN
FY2024 N/A $30M N/A -53.4% CGEN
FY2025 $0M $70M -11910.1% 43.1% CGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MCRB (2) vs CGEN (8)
Institutional Metric MCRB CGEN Criterion Row Winner
Market Capitalization Scale $13.8M $193.2M Larger Scale CGEN
Trailing P/E Ratio Valuation 10.8x 5.2x Lower Multiple CGEN
Forward P/E Ratio Valuation 10.8x 12.4x Lower Multiple MCRB
Revenue Growth (YoY) Growth +68.9% +102.1% Higher Growth CGEN
Operating Margin (TTM) Profitability -3115.1% 41.3% Higher Margin CGEN
Net Profit Margin Profitability 0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency -144.3% 57.2% Higher ROE CGEN
52-Week Range Position Momentum 0% ($1โ€“$30) 33% ($1โ€“$3) Stronger Trend CGEN
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 92% Vol 1.44ฮฒ ยท 62% Vol Lower Realized Risk CGEN
Unified Institutional Score Composite Signal 50.0 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite MCRB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MCRB vs CGEN Buy Guide
MCRB BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live MCRB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MCRB nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.